Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Astellas
Research from Japan and the United States add new data to drug development body of knowledge
November 7th, 2006
New findings from Japan and the United States describe advances in drug development. Study 1: Tumor vessels respond to orally active angiogenesis inhibitor YM-201627. "We developed an oral administration-compatible, small molecular weight antitumor agent, YM-201627 by screening for the inhibition of the proliferation of vascular endothelial growth factor (VEGF)-stimulated human umbilical vein endothelial cells (HUVECs). YM-201627 selectively inhibited the proliferation of various endothelial cell lines induced by VEGF, basic fibroblast growth factor (bFGF), and fetal bovine serum (FBS) (at IC50 s of 0.0039-0.12 mcM), that would not be...
Source: Drug Law Weekly (2006-11-07)
|
